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In the review, the use of the ribonucleases for cancer therapy is discussed. Using of epigenetic mechanisms of regulation — blocking 
protein synthesis without affecting the DNA structure — is a promising direction in the therapy. The ribonucleases isolated from different 
sources, despite of similar mechanism of enzymatic reactions, have different biological effects. The use of enzymes isolated from new 
sources, particularly from plants and fungi, shows promising results. In this article we discuss the new approach for the use of enzymes 
resistant to inhibitors and ribozymes, that is aimed at the destruction of the oncogene specific mRNA and the induction of apoptosis.
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Ribonucleases (RNases) are a large group of hy-
drolytic enzymes that degrade ribonucleic acid (RNA) 
molecules. They are nucleases that catalyze the break-
down of RNA into smaller components. RNases are 
a superfamily of enzymes which catalyzing the degra-
dation of RNA operate at the levels of transcription and 
translation. They can be cytotoxic because the cleavage 
of RNA renders illegible its information. Initially it was 
assumed that the function of these enzymes is a simple 
destruction of polyribonucleotides already fulfilled their 
physiological role. Later, however, it became clear that 
the RNases present in all living cells and biological flu-
ids, like pro- and eukaryotes, perform many important 
vital functions. Some members of this family possess 
a high molecular heterogeneity, with some isoforms that 
exhibit extremely high specificity for cleavage of specific 
loci in the polyribonucleotide chains.
RNases are ubiquitous, with a very short lifespan 
in an unprotected environment. The cytotoxic ef-
fects of RNases include the RNA cleavage leading 
to the inhibition of the protein synthesis and inducing 
apoptosis [1]. The cytotoxic effect can be produced 
by applying RNase on the outside surface of the cell 
but it was found that cytotoxicity increases about 
by 1000 times when enzyme is artificially introduced 
into the cytosol, indicating internalization into the cell 
as the rate limiting step for toxicity [2]. Mi et al. [3] 
showed evidence that RNASEL Arg462Gln and Asp-
541Glu polymorphisms are associated with prostate 
cancer risk and could be low-penetrance prostate 
cancer susceptibility biomarkers.
There are two types of RNases, endoribonucle-
ases and exoribonucleases. Endoribonucleases are 
RNase A, RNase P, RNase H, RNase III, RNase T1, 
RNase T2, RNase U2, RNase V1, RNase I, RNase 
PhyM and RNase V. Exoribonucleases includes 
polynucleotide phosphorylase (PNPase), RNase PH, 
RNase II, RNase R, RNase D, RNase T, oligoribonucle-
ase, exoribonuclease I and exoribonuclease II. These 
enzymes differently cleave various RNA species. 
Recently, researchers have paid attention to RNases 
as possible agents for the cancer treatment. The idea 
of using RNases for the treatment of cancer is to find 
an enzyme selectively damaging cancer cells without 
affecting the surrounding normal [4].
Today, several RNases allocated as possible candi-
dates for anticancer agents [5–9]. The interferon (IFN) 
antiviral investigations and prostate cancer genetics 
have merged on a single-strand specific, regulated 
endoribonuclease. The 2´,5´-oligoadenylate (2´-5´A) 
system is an IFN-regulated RNA decay pathway that 
provides innate immunity against viral infections. 
The biologic action of the 2´-5´A system is mediated 
by RNase L, an endoribonuclease that becomes enzy-
matically active after binding to 2´-5´A. RNase L is also 
implicated in mediating apoptosis in response to both 
viral and nonviral inducers. To study the cellular effects 
of RNase L activation, 2´-5´A was transfected into 
the human ovarian cancer cell line Hey1B. Activation 
of RNase L by 2´-5´A resulted in specific 18S rRNA 
cleavage and induction of apoptosis, as measured 
by TUNEL and annexin V binding assays. In contrast, 
the dimeric form of 2´-5´A, ppA2´p5´A, neither acti-
vated RNase L nor caused apoptosis. Treatment with 
IFN-beta prior to 2´-5´A transfection enhanced cellular 
RNase L levels 2.2-fold and increased the proportion 
of cells undergoing apoptosis (by 40%). However, 
rRNA cleavages after 2´-5´A transfections were not 
enhanced by IFN-beta pretreatments, indicating that 
basal levels of RNase L were sufficient for this acti vity. 
Apoptosis in response to RNase L activation was ac-
companied by cytochrome C release from mitochon-
dria. Induction of apoptosis by either 2´-5´A alone 
or by the combination of 2´-5´A and IFN-beta was 
effectively blocked with either the pancaspase inhibi-
tor, Z-VAD-fmk, or with the caspase 3 inhibitor, DEVD-
fmk. Therefore, activation of RNase L by 2´-5´A leads 
to cytochrome C release into the cytoplasm and then 
to caspase activation and apoptosis. These results 
suggest potential uses for 2´-5´A in augmenting the 
anticancer activities of IFN [10].
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The RNASEL gene, a strong candidate for the 
hereditary prostate cancer 1 (HPC1) allele, encodes 
a single-stranded specific endoribonuclease involved 
in the antiviral actions of IFNs. Xiang et al. [11] have 
shown that RNase L is activated enzymatically after 
binding to unusual 5´-phosphorylated, 2´,5´-linked 
oligoadenylates (2´-5´A). Biostable phosphorothio-
ate analogues of 2´-5´A were synthesized chemically 
and used to study the effects of naturally occurring 
mutations and polymorphisms in RNASEL. The 2´-
5´A analogues induced RNase L activity and caused 
apoptosis in cultures of late-stage, metastatic hu-
man prostate cancer cell lines DU145, PC3, and 
LNCaP. However, DU145 and PC3 cells were more 
sensitive to 2´-5´A than LNCaP cells, which are 
heterozygous for an inactivating deletion mutation 
in RNase L. The RNase activities of missense variants 
of human RNase L were compared after expression 
in a mouse RNase L(-/-) cell line. Several variants 
(G59S, I97L, I220V, G296V, S322F, Y529C, and D541E) 
produced similar levels of RNase L activity as wild-type 
enzyme. In contrast, the R462Q variant, previously 
implicated in up to 13% of unselected prostate cancer 
cases, bound 2´-5´A at wild-type levels but had a 3-fold 
decrease in RNase activity. The deficiency in RNase 
L activity (R462Q) was correlated with a reduction in its 
ability to dimerize into a catalytically active connect. 
Furthermore, RNase L (R462Q) was deficient in cau-
sing apoptosis in response to 2´-5´A consistent with its 
possible role in prostate cancer development. Authors 
support the notion that RNASEL mutations allow tumor 
cells to escape a potent apoptotic pathway [11].
Genetics studies from several laboratories 
in the U.S., Finland, and Israel, support the re-
cent identification of the RNase L gene, RNASEL, 
as a strong reason for the HPC1. Results from these 
studies suggest that mutations in RNASEL predispose 
men to an increased incidence of prostate cancer, 
which in some cases reflect more aggressive disease 
and/or decreased age of onset compared with non-
RNASEL linked cases. RNase L is a uniquely regulated 
endoribonuclease that requires 5´-triphosphorylated, 
2´,5´-linked oligoadenylates (2´-5´A) for its activity. 
The presence of both germline mutations in RNASEL 
segregating with disease within HPC-affected families 
and loss of heterozygosity in tumor tissues suggest 
a novel role for the regulated endoribonuclease in the 
pathogenesis of prostate cancer. The association 
of mutations in RNASEL with prostate cancer cases 
further suggests a relationship between innate im-
munity and tumor suppression. It is proposed that 
RNase L functions in counteracting prostate cancer 
by virtue of its ability to degrade RNA, thus initiating 
a cellular stress response that leads to apoptosis [12, 
13]. The HPC1 allele maps to the RNASEL gene en-
coding a protein (RNase L) implicated in the antiviral 
activity of IFNs.
To investigate the possible role of RNase L in apop-
tosis of prostate cancer cells, Malathi et al. [14] 
decreased levels of RNase L by several fold in the 
DU145 human prostate cancer cell line through the 
stable expression of a small interfering RNA (siRNA). 
Control cells expressed siRNA with three mismatched 
nucleotides to the RNase L sequence. Cells deficient 
in RNase L, but not the control cells, were highly 
resistant to apoptosis by the RNase L activator, 2´-
5´A. At the same time, the RNase L-deficient cells 
were also highly resistant to apoptosis by combination 
treatments with a topoisomerase (Topo) I inhibitor 
(topotecan) and tumor necrosis factor-related apop-
tosis-inducing ligand TRAIL (Apo2L). In contrast, cells 
expressing siRNA to the RNase L inhibitor RLI (HP68) 
showed enhanced apoptosis in response to Topo I in-
hibitor alone or in combination with TRAIL. An inhibitor 
of c-Jun NH(2)-terminal kinases reduced apoptosis 
induced by treatment with either 2´-5´A or the com-
bination of camptothecin and TRAIL, thus implicating 
c-Jun NH(2)-terminal kinase in the apoptotic signaling 
pathway. Likewise, prostate cancer cells were sensitive 
to apoptosis from the combination of 2´-5´A with either 
TRAIL or Topo I inhibitor, whereas normal prostate 
epithelial cells were partially resistant to apoptosis. 
These findings indicate that RNase L integrates and 
amplifies apoptotic signals generated during treatment 
of prostate cancer cells with 2´-5´A, Topo I inhibitors, 
and TRAIL [14].
Montia et al. [15] found that an extracellular RNase 
is involved in the control of ovarian tumorigenesis. They 
shown that the loss of function of RNase T2, an ancient 
and phylogenetically conserved RNase, plays a crucial 
role in ovarian tumorigenesis.
The above data were the basis for many attempts 
to use RNases for cancer therapy. Currently, it is shown 
that the RNases isolated from different sources, have 
antitumour activity. In some cases, studies reported 
to the clinical trials.
Bovine seminal RNase (BS-RNase). The RNase 
found in bull semen, displays antitumor, antispermato-
genic, and immunosuppressive activities. Besides its 
unique structure and enzymatic properties seminal 
RNase belongs to an interesting group of RNases, the 
RISBASES (RNases with Special, Biological Actions), 
other members of which include angiogenin, selec-
tively neurotoxic RNases, a lectin and the incompa-
tibility factors from a flowering plant [16].
BS-RNases, a dimeric protein found to be homoge-
neous by several standard criteria of purity, is hetero-
geneous when analyzed by ion-exchange chromato-
graphy on carboxymethylcellulose. Three increasingly 
cationic subforms can be separated. The heterogene-
ity is due to the presence of two types of subunits, al-
pha and beta, which make up three isoenzymic dimers: 
alpha 2, beta 2, and alpha beta. Deamidation reactions 
can convert the most cationic beta 2 subform into the 
alpha beta subform, which in turn can be converted 
into stable alpha 2 subform. These conversions involve 
the hydrolysis of 2 mol of differentially labile amide 
groups per mol of protein. The ratios alpha 2: alpha 
beta: beta 2 are constant in all preparations of seminal 
RNase tested; they are independent of the purification 
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procedure as well as of the biological source of the 
enzyme (seminal plasma or seminal vesicles). These 
results indicate that deamidations occur in vivo before 
the protein is secreted from the seminal glands. They 
also suggest that heterogeneity of seminal RNase 
reflects a physiological need of distinct molecular 
forms of enzyme or, alternatively, a process which 
leads to the aging of the protein [17]. The cytotoxic 
effect of BS-RNase on tumor cells is accompanied 
by the induction of apoptosis [17].
Sinatra et al. [18] provide ultrastructural and flow 
cytometry evidence of apoptotic death following BS-
RNase treatment, in normal cells and phytohemag-
glutinin-stimulated lymphocytes. Transmission and 
scanning electron microscopy, which were fully sup-
ported by flow cytometry data, showed typical features 
of apoptosis, such as decreased cell size, chromatin 
condensation, fragmentation in micronuclei, and the 
presence of apoptotic bodies. BS-RNase is a homo-
logue of bovine pancreatic ribonuclease (RNase A).
Unlike RNase A, BS-RNase has notable toxicity for 
human tumor cells. Wild-type BS-RNase is a homodi-
mer linked by two intermolecular disulfide bonds. This 
quaternary structure endows BS-RNase with resistance 
to inhibition by the cytosolic ribonuclease inhibitor 
protein (RI), which binds to RNase A and monomeric 
BS-RNase. Authors report on the creation and analysis 
of monomeric variants of BS-RNase that evade RI but 
retain full enzymatic activity [19]. The cytotoxic activity 
of these monomeric variants exceeds that of the wild-
type dimer by up to 30-fold, indicating that the dimeric 
structure of BS-RNase is not required for cytotoxicity. 
Dimers of these monomeric variants are more cytotoxic 
than wild-type BS-RNase, suggesting that the cytoto-
xicity of the wild-type enzyme is limited by RI inhibition 
following dissociation of the dimer in the reducing 
environment of the cytosol. Finally, the cytotoxic acti-
vity of these dimers is less than that of the constituent 
monomers, indicating that their quaternary structure 
is a liability. These data provide new insight into struc-
ture — function relationships of BS-RNase. Moreover, 
BS-RNase monomers described herein are more toxic 
to human tumor cells than is any known variant or homo-
logue of RNase A including ranpirnase, an amphibian 
homologue in phase III clinical trials for the treatment 
of unresectable malignant mesothelioma [20].
Onconase (ranpirnase) is a first-in-class therapeu-
tic product based on Alfacell’s proprietary RNase tech-
nology. A natural protein isolated from the leopard frog 
Rana pipiens, ranpirnase has been shown in the labo-
ratory and clinic to target cancer cells while sparing 
normal cells. Ranpirnase triggers apoptosis, the natu-
ral death of cells, via multiple molecular mechanisms 
of action [21]. Ranpirnase is a novel RNase which 
preferentially degrades tRNA, thus leading to inhibition 
of protein synthesis and, ultimately, to cytostasis and 
cytotoxicity. Ranpirnase has demonstrated antitumor 
activity both in vitro and in vivo in several tumor mod-
els [22, 23]. The maximum tolerated dose emerging 
from phase I studies was 960 g/m2, with renal toxicity 
as the main dose-limiting toxicity. A large phase II trial 
showed that ranpirnase has disease-modifying activity 
against malignant mesothelioma. Ranpirnase proved 
to be general caspase inhibitors strongly suggest that 
the signaling pathways triggered by the death stimuli 
diverge into one pathway leading to caspase activa-
tion (PARP processing, DNA degradation, and annexin 
V binding) and another leading to mRNA degradation. 
In addition, data obtained show that extensive mRNA 
degradation, although apparently a general early 
apoptotic event, is not sufficient to induce cell death 
per se. The molecular mechanisms implicated in apop-
tosis-induced mRNA degradation are not known. 
The apoptotic stimuli leads to activation of an RNase 
dependent on an upstream apical caspase (inhibited 
by Z-VAD-fmk, but not p35, and unable to cleave 
PARP) in a similar manner as CAD (caspase-activated 
DNase) activation. Conversely, activation of the RNase 
may be independent of caspase activation but still 
inhibited by Z-VAD-fmk [24]. Ranpirnase has been 
granted fast track status and orphan-drug designation 
for the treatment of malignant mesothelioma by the 
Food and Drug Administration. Additionally, ranpirnase 
has been granted orphan-drug designation in the 
Euro pean Union and Australia.
In April, 2006 Alfacell released interim data from 
the company’s ongoing Phase IIIb randomized clinical 
trial of ranpirnase and doxorubicin for the treatment 
of malignant mesothelioma. The study reached the first 
interim analysis at 105 events (patient deaths) of the 
total 316 patients enrolled. Interim data demonstrate 
that the overall median survival time favored the ran-
pirnase plus doxorubicin treatment group (12 months) 
over the doxorubicin group (10 months). It has been 
tested and found to be cytotoxic to cancer cells be-
cause of its enzymatic activity against RNA.
Ranpirnase is internalized by endocytosis and 
released into the cytosol of the cancerous cell, where 
it selectively degrades tRNA beyond repair. In doing so, 
ranpirnase inhibits protein synthesis, stops cell cycle 
proliferation, and induces apoptosis [25].
USA-based Tamir Biotechnology (formerly Alfacell) 
says that scientists supported by the National Institute 
of Allergy and Infectious Diseases (NIAID) reported 
test results confirming two of its lead compounds 
showed excellent in vitro antiviral activity and no cel-
lular toxicity at dose levels tested for human papillo-
mavirus (HPV). Testing was performed using the HPV 
11 strain, which along with HPV type 6, is responsible 
for 90% of genital or anal warts [26].
Ranpirnase is a cytotoxic RNase which targets 
tumor cells in vivo and in vitro. To date, cellular tRNA 
appeared to be the major target for ranpirnase medi-
ated cytotoxic activity. Saxena et al. [27] demonstrated 
that ranpirnase can also cleave double-stranded 
RNA (dsRNA). Incubation of ranpirnase at 37 °C with 
GAPDH gene-dsRNA (~440 bp long) and dsRNA lad-
der showed degradation of dsRNA into a spectrum 
of smaller dsRNA fragments. Moreover, incubation 
of dsRNA substrates at 40 °C under similar conditions 
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markedly potentiated further cleavage of dsRNAs. The 
recently discovered double-stranded RNase activity 
of ranpirnase suggests another mechanism for induc-
ing cell death/apoptosis in malignant phenotypes via 
the RNA interference mechanism involving siRNA and 
miRNA [27]. Another enzyme sialic acid-binding lectin 
(SBL), isolated from oocytes of Rana catesbeiana, 
is leczyme and has both lectin and RNase activities [8]. 
SBL agglutinates various kinds of tumor cells but not 
normal cells. SBL agglutination activity is not affected 
by mono- or oligosaccharides. However, SBL-induced 
agglutination and antitumor effects are inhibited by si-
alomucin but not asialomucin. SBL causes cancer-
selective induction of apoptosis by multiple signaling 
pathways, which target RNA [8].
RNase T1 is an endonuclease (EC 3.1.27.3), iso-
lated from fungi, which cuts the single-stranded RNA 
molecules after guanine residues, i.e., at the 3´ end. 
RNase T1 is the best known representative of a large 
family of ribonucleolytic proteins secreted by fungi, 
mostly Aspergillus and Penicillium species. Ribotoxins 
stand out among them by their cytotoxic character. 
They exert their toxic action by first entering the cells 
and then cleaving a single phosphodiester bond lo-
cated within a universally conserved sequence of the 
large rRNA gene, known as the sarcin — ricin loop. 
This cleavage leads to inhibition of protein biosynthe-
sis, followed by cellular death by apoptosis. Although 
no protein receptor has been found for ribotoxins, 
they preferentially kill cells showing altered membrane 
permeability, such as those that are infected with virus 
or transformed.
The most-studied form of the enzyme RNase 
T1 is the mold of Aspergillus oryzae and Penicillium 
species. RNase T1 is a small protein α + β, consisting 
of 104 amino acid residues. Protein structure contains 
four antiparallel beta pleated sheets covered nearly 
five turnovers long alpha-helix. RNase T1 has two di-
sulfide bonds Cys2-Cys10 and Cys6-Cys103, the latter 
of which is involved in the installation [28] and the full 
restoration of disulfide bonds leads to the unfolding 
of the protein [29].
Due to the specificity guanine RNase T1 frequently 
used for cleavage of RNA denatured prior to sequenc-
ing. Like other RNases, for example RNase A, RNase 
T1 is a popular subject for study of protein folding [30].
So, ranpirnase and α-sarcin are known to be toxic 
to tumor cells, and on the other hand, their structure 
is related to that of RNase T1, latter is noncytotoxic 
because of its inability to internalize into tumor cells. 
In their study, Yuki et al. [31] internalized RNase T1 into 
human tumor cells via a novel gene transfer reagent, 
hem-agglutinating virus of Japan (HVJ) envelope vec-
tor, which resulted in cell death. This cytotoxicity was 
drastically increased by pretreatment of HVJ envelope 
vector with protamine sulfate, and was stronger than 
that of ranpirnase, which is in phase III human clinical 
trials as a nonmutagenic cancer chemotherapeutic 
agent. Furthermore, internalized RNase T1 induced 
apoptotic cell death programs. Because its cytotoxic-
ity is unfortunately not speci�c to tumor cells, it can-totumorcells,itcan-
not at present be developed as an anticancer drug. 
However, authors believe that RNase T1 incorporated 
in HVJ envelope vector will be a unique anticancer 
drug if HVJ envelope vector can be targeted to tumor 
cells [28, 32].
Specific complexes of protein and RNA carry out 
many essential biological functions, including RNA 
processing, RNA turnover, RNA folding, as well as the 
translation of genetic information from mRNA into pro-
tein sequences. Messenger RNA (mRNA) decay is now 
emerging as an important control point and a major 
contributor to gene expression. Continuing identifica-
tion of the protein factors and cofactors, and mRNA 
instability elements responsible for mRNA decay allow 
researchers to build a picture of the special processes 
involved in mRNA decay and its regulation [33].
Presently known data demonstrate that apoptosis-
induced mRNA degradation is an early event triggered 
by different apoptotic signals, occurring not only in in vi-
tro models but also in vivo. It is not restricted to genes 
with a specific function, since besides 28S rRNA, it af-
fects mRNA coding for proteins implicated in a variety 
of functions, including cell type-specific functions 
such as HLA-I, IAα, TCRβ, and CD69, structural func-
tions such as β-actin, or control of cell survival, such 
as BAX. There is evidence that potassium channels, 
the NF-κB signaling pathway, and various caspases 
play a role in exogenous RNase-induced apoptosis [9].
Apoptosis-induced mRNA degradation is an active 
process that induces a similar decay kinetics (t1/2 be-
tween 1.5 and 3 h) of mRNAs with very different intrinsic 
half-lives (from 20 min to > 10 h). Kinetic experiments 
using stimuli diverge into one pathway leading to cas-
pase activation (PARP processing, DNA degradation, 
and annexin V binding) and another leading to mRNA 
degradation were held. In addition, the data obtained 
show that extensive mRNA degradation, although ap-
parently a general early apoptotic event, is not sufficient 
to induce cell death per se. The molecular mechanisms 
implicated in apoptosis-induced mRNA degradation 
are not known. Nonetheless, it seems that the apop-
totic stimuli leads to activation of an RNase dependent 
on an upstream apical caspase (inhibited by Z-VAD-fmk, 
but not p35, and unable to cleave PARP) in a similar 
manner as CAD activation. Conversely, activation of the 
RNase may be independent of caspase activation but 
still inhibited by Z-VAD-fmk [34].
Actibind and RNase T2. Actibind, a protein that 
is produced by the black molds Aspergillus niger, 
a well-known microorganism used in bio and food 
industry [32]. In plants, actibind binds actin, a major 
component of the intracellular structure in plants, in-
terfering with the plants’ pollen tubes and halting cell 
growth. Actibind can also affect mammalian cancer 
development [35]. RNase T2, was also subsequently 
found to bind actin in human and animal migrating 
cells, such as the cells that are responsible for new 
blood vessel formation (angiogenesis) in tumors thus 
blocking the blood supply to the tumors, actibind 
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halted the ability of malignant cells to move through 
the blood stream to form new metastases [36].
A further plus is that actibind is not toxic to normal 
cells, thereby significantly minimizing the risk of side 
effects. The fungal actibind and the human RNase 
T2 represent the basis for a new class of drugs that 
could be used as a front-line therapy in the fight 
against cancer.
α-Sarcin. α-Sarcin, mitogillin, and restrictocin 
are small (approximately 17 kDa) basic ribosome-
inactivating proteins (RIPs) produced by the Aspergilli 
that catalytically inactivate the large ribosomal subunits 
of all organisms tested to date. These three fungal ribo-
toxins act as specific RNases by hydrolyzing one single 
phosphodiester bond in the universally conserved 
alpha-sarcin domain of 23–28S rRNAs and are among 
the most potent inhibitors of protein synthesis known.
Previous molecular studies of ribotoxins indicated 
that they belong to the superfamily of RNases and 
analysis of the mitogillin gene employing PCR-mediated 
site-specific mutagenesis suggests that certain do-
mains in ribotoxins, which share homologies with motifs 
in ribosome-related proteins, may be responsible for the 
targeting of ribotoxins to the ribosome. The applications 
of the ribotoxins as tools in research and their using 
as therapeutic and diagnostic agents are reviewed [37]. 
α-Sarcin is a potent polypeptide toxin (cyclising RNase) 
of 150 residues secreted by the fungus Aspergillus gi-
ganteus MDH18894 that belongs to the type 1 (those 
having only single polypeptide chain) group of the 
ribosome-inactivating enzyme. It is the most significant 
member of the family of fungal ribotoxins that display 
a 3-dimensional structure.
His50, Glu96, His137 residues of α-sarcin in-
volved in the mechanism of catalysis. The hydrolysis 
of 3´-5´phosphodiester bond of the substrate yielding 
2´-3´ cyclic mononucleotide and then conversion of the 
intermediate into the corresponding 3´-monophos-
phate derivative as the final product of the reaction. 
Thus, α-sarcin acts by cleavage of the phosphodiester 
bond of 28S rRNA, stops the protein synthesis. In addi-
tion to this enzymatic activity α-sarcin interacts with the 
lipid bilayers promoting their fusion and leakage. Any 
toxin that is able to produce more than 90% of inhibition 
of protein synthesis may induce apoptosis [38, 39].
α-Sarcin is active against transformed or virus-
infected mammalian cells, in the absence of any other 
permeabilizing agent [40, 41]. RNases distinct from 
ubiquitin-like peptides and proteins were isolated 
from several mushroom species. One of RNases was 
isolated from Pleurotus sajor-caju; it exerts an anti-
proliferative action on hepatoma and leukemia cells, 
and anti-mitogenic action on mouse spleen cells [42]. 
Recently was shown that antiproliferative activity can 
be attributed to enzymes which inactivate ribosomes 
by eliminating one or more adenosine residues from 
rRNA. During the past decade, mushroom inactivating 
proteins were isolated from several species including 
Calvatia caelata, F. velutipes, H. marmoreus, Lyophyl-
lum shimeiji, and Pleurotus tuber-1 ribosome [43, 44].
RNase P. RNase P is unique from other RNases 
in that it is the ribozyme, i.e. RNA that acts as a cata-
lyst in the same way that the protein based enzyme 
would. Its function is to cleave off the extra or precur-
sor sequence of RNA on RNA molecules. In the current 
cancer therapy, the main problem is to distinguish be-
tween the cancer cells and the normal cells. There are 
certain chimeric molecules, which are specific to the 
cancer cells, which can act as the specific targets and 
thus solving the problem [45]. M1 RNA is the catalytic 
subunit of RNase P and this subunit catalyses the hy-
drolytic removal of 5´-leader sequence of t-RNA. Stu-
dies of the substrate recognition by M1 RNA have led 
to the development of the strategy of gene targeting 
by M1 RNA [45]. M1 RNA can be targeted to the mRNA 
simply by the addition of the so-called guide sequence 
at the 3´-terminal. So this now becomes as M1-GS, 
which has mRNA as its target. Cleavage of the mRNA 
will not allow the formation of the fusion proteins, which 
are specific for the cancer cells. The utility of the M1-
GS in the cancer was shown by its use against BCR-ABL 
oncogene model [45]. This BCR-ABL oncogene was 
created by the translocation of the sequences from 
ABL gene on chromosome 9 to the BCR gene on the 
chromosome 22 [46]. Two oncogenes were created 
BCR-ABL p190 and BCR-ABL p210. Both of these 
differ and have identical ABL derived sequences but 
differ in the number of the BCR nucleotides. These 
chimeric molecules so formed by the chromosomal 
rearrangement would be specific to the cancer cells 
and thus serve as the excellent targets. These BCR-
ABL oncogenes are responsible for the myelogenous 
leukemia and acute lymphoblastic leukemia [47]. BCR-
ABL oncogenes inhibit the apoptosis by Bcl-2 pathway 
as a part of their oncogenic phenotype. Inhibition of the 
BCR-ABL expression would thus reverse this phenotype 
and the cells die by apoptosis. It should be noted that 
M1-GS should target only at the junction sequences 
of the transcribed mRNA. If not so then the mRNA of the 
normal cells would be cleaved and thus the resultant 
damage to the normal cells would occur. This gene 
therapy promises to be an effective strategy for the 
future treatment of the cancer.
Using only this BCR-ABL system, model has created 
the RNase P technology for the inhibition of the chimeric 
gene products and the efficiency of the agents has not 
been evaluated in the animal models to our knowledge 
and thus the efficiency of the delivery process is still 
a major problem to be investigated and solved. But 
surely this advancement provides a new therapeutic tool 
for the treatment of cancer and holds some promise for 
more selective, non-toxic cancer therapy in the future.
These data show that the sources of bioactive 
RNases may be of different origin. It is known that 
a huge amount of unexplored RNases contain plants. 
Vegetation, as well as the world of fungi, presents 
a potentially inexhaustible source of these enzymes. 
It can be expected that some of these will possess 
anti-tumor activity. From the above it is clear that fur-
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ther study of antitumor action of RNases is possible 
in several directions.
1. The search for new sources of the enzymes with 
the new physiological properties. In this regard, we can 
point to such a source as the plants and fungi. It is known 
that the flora is characterized by an exceptionally large 
variety of RNases. It can be expected that some of these 
will possess anti-tumor activity. An important source 
of the enzymes can also be mushrooms. Well-known 
antitumor activity of many fungi at least partially may 
be explained by their enzymatic activity.
2. The study must be focused on the search for new 
inducers of RNases activity in the tissues, including 
tumor tissue. The same way the latent RNase L is ac-
tivated by 2´-5´A which in turn is synthesized under 
the influence of IFN.
3. Chemical modification of known RNases to en-
hance their resistance to intracellular inhibitors.
4. Creation of new ribozyme-type highly specific 
RNases aimed to the precise destruction of the pro-
ducts of oncogenes.
5. Perspective can be also combined use of RNases 
with known anticancer drugs. We believe that further 
development of these studies will be a prerequisite for 
the creation of new effective agents for the treatment 
of cancer.
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